A Dolon Institute Publication – UICC World Cancer Congress 2026
Authored by
Amanda Whittal, Senior Principal, and Isabelle Lawrence, Engagement Manager at Prescient.
Executive summary
In September 2026, the Dolon Institute powered by Prescient convened a multi-stakeholder panel at the UICC World Cancer Congress in Hong Kong as part of the ONWARD initiative. The panel brought together perspectives from policy, patient advocacy, clinical practice and industry. It explored how to advance meaningful innovation in oncology and address persistent challenges in patient access to novel cancer therapies.
The discussion built on the ONWARD white paper, published in June 2026, which identified six key barriers limiting access to oncology innovation across healthcare and payer systems. These range from gaps in diagnosis, referral pathways and specialist workforce capacity to the difficulty of assessing clinical benefit, managing budget constraints and delivering increasingly complex therapies. Panellists shared insights and practical solutions for each barrier, drawing on examples from China, Australia and global patient research.
Three key themes emerged from the discussion
Patient centricity must be at the heart of decision-making. Across diagnosis, clinical care, evidence development and policymaking, understanding and responding to patient needs is essential to driving meaningful progress.
Access challenges are interconnected and require collective action. Barriers are unlikely to be resolved in isolation. Lasting solutions depend on coordinated collaboration across stakeholders.
There is much to learn from solutions being implemented globally. Approaches may not transfer directly between healthcare systems, but sharing experiences and learnings can help inform solutions to common access challenges.
The discussion reinforced the importance of continued collaboration to support meaningful, accessible innovation for patients with cancer worldwide.
Download the full report to explore the panel’s insights and solutions for advancing equitable access to cancer care.
The panel and accompanying white paper are sponsored outputs of the ONWARD (Oncology Needs, Workforce, Access, Research & Disparities) initiative, supported by AbbVie, which aims to promote awareness and multi-stakeholder dialogue on these issues.
Contact us